AGLE-102
Small molecule
AGLE-102 is one of 6 small molecule programs targeting Dystrophic epidermolysis bullosa. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Dystrophic Epidermolysis Bullosa
#DrugCompanyPhaseTrials
1Granulocyte Colony-Stimulating Factor
SanofiPhase 2
Neupogen
EEastern Cooperative Oncology Group
Phase 2
Immunoglobulin G
CSL BehringPhase 2
HP802-247
HHealthpoint
Phase 2
ALLO-ASC-SHEET
AAnterogen Co., Ltd.
Phase 2
AGLE-102
AAegle Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AGLE-102. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- AAegle Therapeutics